424 related articles for article (PubMed ID: 22443303)
1. Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era.
Sanmartin R; de Felipe E; Tor J; Sanvicens A; Barluenga E; Martinez E; Muga R; Jou A; Ojanguren I; López JJ; Clotet B; Tural C
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1235-43. PubMed ID: 22443303
[TBL] [Abstract][Full Text] [Related]
2. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
[TBL] [Abstract][Full Text] [Related]
3. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV.
Limketkai BN; Mehta SH; Sutcliffe CG; Higgins YM; Torbenson MS; Brinkley SC; Moore RD; Thomas DL; Sulkowski MS
JAMA; 2012 Jul; 308(4):370-8. PubMed ID: 22820790
[TBL] [Abstract][Full Text] [Related]
4. Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy.
Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; Soriano V
AIDS; 2013 Apr; 27(7):1129-34. PubMed ID: 23276803
[TBL] [Abstract][Full Text] [Related]
5. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
[TBL] [Abstract][Full Text] [Related]
6. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
[TBL] [Abstract][Full Text] [Related]
7. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.
Labarga P; Fernandez-Montero JV; de Mendoza C; Barreiro P; Pinilla J; Soriano V
Antivir Ther; 2015; 20(3):329-34. PubMed ID: 25372299
[TBL] [Abstract][Full Text] [Related]
8. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.
Macías J; Berenguer J; Japón MA; Girón JA; Rivero A; López-Cortés LF; Moreno A; González-Serrano M; Iribarren JA; Ortega E; Miralles P; Mira JA; Pineda JA
Hepatology; 2009 Oct; 50(4):1056-63. PubMed ID: 19670415
[TBL] [Abstract][Full Text] [Related]
9. Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon.
McGovern BH; Birch C; Zaman MT; Bica I; Stone D; Quirk JR; Davis B; Zachary K; Basgoz N; Graeme-Cook F; Gandhi RT
Clin Infect Dis; 2007 Nov; 45(10):1386-92. PubMed ID: 17968840
[TBL] [Abstract][Full Text] [Related]
10. Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy.
Macías J; Márquez M; Téllez F; Merino D; Jiménez-Aguilar P; López-Cortés LF; Ortega E; von Wichmann MA; Rivero A; Mancebo M; Santos J; Pérez-Pérez M; Suárez-Lozano I; Romero-Palacios A; Torres-Cornejo A; Pineda JA
Clin Infect Dis; 2013 Nov; 57(10):1401-8. PubMed ID: 23946224
[TBL] [Abstract][Full Text] [Related]
11. HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients.
Cooper C; Rollet-Kurhajec KC; Young J; Vasquez C; Tyndall M; Gill J; Pick N; Walmsley S; Klein MB;
HIV Med; 2015 Jan; 16(1):24-31. PubMed ID: 24837567
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
[TBL] [Abstract][Full Text] [Related]
13. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
Fuster D; Planas R; Muga R; Ballesteros AL; Santos J; Tor J; Sirera G; Guardiola H; Salas A; Cabré E; Ojanguren I; Barluenga E; Rey-Joly C; Clotet B; Tural C
AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1293-7. PubMed ID: 15650421
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.
Benhamou Y; Di Martino V; Bochet M; Colombet G; Thibault V; Liou A; Katlama C; Poynard T;
Hepatology; 2001 Aug; 34(2):283-7. PubMed ID: 11481613
[TBL] [Abstract][Full Text] [Related]
15. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM;
Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643
[TBL] [Abstract][Full Text] [Related]
16. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Merchante N; Rivero-Juárez A; Téllez F; Merino D; José Ríos-Villegas M; Márquez-Solero M; Omar M; Macías J; Camacho A; Pérez-Pérez M; Gómez-Mateos J; Rivero A; Antonio Pineda J;
Hepatology; 2012 Jul; 56(1):228-38. PubMed ID: 22278746
[TBL] [Abstract][Full Text] [Related]
17. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.
Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D;
J Viral Hepat; 2011 Jul; 18(7):e307-14. PubMed ID: 21692942
[TBL] [Abstract][Full Text] [Related]
18. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies.
Labarga P; Fernández-Montero JV; López M; Barreiro P; de Mendoza C; Sierra-Enguita R; Treviño A; Soriano V
Antivir Ther; 2014; 19(8):799-803. PubMed ID: 24964405
[TBL] [Abstract][Full Text] [Related]
19. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
[TBL] [Abstract][Full Text] [Related]
20. Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals.
Rohrbach J; Stickel F; Schmid P; Thormann W; Kovari H; Scherrer A; Günthard HF; Vuichard D; Cavassini M; Ambrosioni J; Bernasconi E; Furrer H; Rauch A;
Antivir Ther; 2014; 19(2):149-59. PubMed ID: 24036684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
